Format

Send to

Choose Destination
Nat Rev Cancer. 2006 Aug;6(8):626-35. Epub 2006 Jul 13.

Predicting benefit from anti-angiogenic agents in malignancy.

Author information

1
Academic Unit of Pathology, Leeds Institute for Molecular Medicine, University of Leeds, UK. adrianjubb@gmail.com

Abstract

A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.

PMID:
16837971
DOI:
10.1038/nrc1946
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center